CF News Media Kit - 2015

2015MEDIA KIT

BioNews Services, LLC, 5307 E. Mockingbird Lane, Fifth Floor, Dallas, TX 75206(972) 971-2793, [email protected]

No other science or research-related publication on the web is producing news on a daily basis for multiple sclerosis patients, caregivers and HCPs. Cystic Fibrosis News Today (CFNT) is filling an unmet need in healthcare news journalism by providing patients and their families with a reliable CF focused news journal they can engage with on a daily basis for the latest news and CF resources.

Our high level of commitment to the CF patient population and the consistency in which we publish news leads to a level of trust and authority that filters down to our clients. Advertising on CFNT provides companies a non-branded approach to generating awareness and promoting their brand, product or service to a user base that is both targeted and open to messaging that pertains to their disease focus.

On average, we publish 20 – 30 new CF related original content articles each month, keeping the patient and caregiver population informed and empowered with news and information delivered in near real-time.

We enjoy industry leading engagement, trust and credibility with our readers. CFNT’s writing team boasts a diverse array of talented, experienced professionals. Our team includes PhDs, journalists,

biotech business professionals, and online marketing experts, all of whom come together to create one of the leanest, most flexible digital content-based marketing platforms on the web today.

This content model, together with our aggressive demographic targeting via social media and search engine optimization ensures that ads on CFNT perform far above industry benchmarks for click-through rates (CTR) and conversions. The only users interacting with CFNT content are people interested in multiple sclerosis, as a result, there are no wasted impressions or empty ad visibility – guaranteeing that client’s products or brands are in front of a highly targeted audience.

BioNews Services, LLC, 5307 E. Mockingbird Lane, Fifth Floor, Dallas, TX 75206(972) 971-2793, [email protected]

CF News Reader Survey

Reader Profile

a. Visit most often

0 5 10 15 20 25 30 35 40

OtherMedical Xpress MedPage Today

Medical News TodayEveryday Health

WebMDCF Foundation

Cystic Fibrosis News Today

1.02%

0.00%0.00%

0.00%0.00%

19.39%

c. Trust

b. Frequency

39.80%39.80%

a. CFTR Mutation b. Gender

d. Easy to understand e. Meet needs

0

5

10

15

20

25

30

35

40

NOT ATALL EASY

NOT SOEASY

MODERATELYEASY

VERYEASY

EXTREMELYEASY

32.74%

38.05%

28.32%

0.88%0.00%

0

10

20

30

40

50

60

NOT ATALL WELL

NOT SOWELL

MODERATELYWELL

VERYWELL

EXTREMELYWELL

24.78%

53.98%

20.35%

0.88% 0.00%

Female

59.79%

Male

40.21%

c. Associated conditions

0 5 10 15 20 25 30 35 40

OTHER

DIABETES

NUTRITIONAL DEFICIENCIES

COLLAPSED LUNG

PNEUMOTHORAX

NASAL POLYPS

MRSA INFECTION

BRONCHIECTASIS 22.86%

35.71%

37.86%

5.00%

5.71%

27.86%

34.29%

30.71%

0 10 20 30 40 50 60OTHER

DON’T KNOW/UNSURER117HR553X

N1303KW1282X

G551D G542X

F508DEL 59.79%

2.58%

2.06%

3.61%

0.52%

1.03%

2.06%

6.70%

21.65%

d. Therapy

OTHER

VITAMINS

ENZYME REPLACEMENT THERAPY

INHALED ANTIBIOTICS

INTRAVENOUS ANTIBIOTICS

ORAL ANTIBIOTICS

HYPERTONIC SALINE

BRONCHODILATOR

TOBI PODHALER

PULMOZYME

HFCWO DEVICE - VEST

KALYDECO

visits per week

0

20

40

60

5 or more 3-52-31

50.89%

29.46%

13.39%

6.25%

42.48%

45.13%

11.50%

0.00%

0.88%

0 10 20 30 40 50

NOT AT ALL

A LITTLE

A MODERATEAMOUNT

A LOT

A GREATDEAL

BioNews Services, LLC, 5307 E. Mockingbird Lane, Fifth Floor, Dallas, TX 75206(972) 971-2793, [email protected]

Social Media

0.0 0.2 0.4 0.6 0.8 1.0

Boomer Esiason

CF Trust

CF Foundation

WebMD

CF News Today 0.89

0.095

0.051

0.073

0.101

Number3,700+

Open36.2%

Click Rate8.3%

Time on page2m 42s

Device

33.31%

Acquisition

ReferralDirect

OrganicSocial 54.7%

28.6%13.2%

3.5%Desktop

Mobile 66.69%

a. Facebook

b. Other social media accounts

Twitter, Pinterest, Google+, LinkedIn

Likes – 9,600+

Engagement / Like

i.

Facebook Overview (30 Days)

New Fans – 266

Engagement – 46,738

Reach – 1,751,279 Clicks – 38,350

Share – 7,704

Comments – 1,807

Email list

Analytics